Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.
Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.
Front Biosci (Landmark Ed). 2024 Oct 8;29(10):349. doi: 10.31083/j.fbl2910349.
The immune system and cancer cells interact intricately during the growth of tumors, and the dynamic interplay between immune activation and suppression greatly influences the cancer outcome. Natural killer cells (NK), cytotoxic T lymphocytes (CTLs) and Dendritic cells (DC), employ diverse mechanisms, to combat cancer. However, the challenges posed by factors such as chronic inflammation and the immunosuppressive tumor microenvironment (TME) often hinder immune cells' ability to detect and eliminate tumors accurately. Immunotherapy offers a promising approach, reprogramming the immune system to target and eliminating cancer cells while minimizing side effects, enhancing immune memory, and lowering the risk of metastasis and relapse compared to traditional treatments like radiation and surgery. Nanotechnology presents a potential solution by enabling safer, more efficient drug delivery through nanoparticles. These nanoengineered drugs can be tailored for controlled activation and release. Improving TME characters holds potential for enhancing personalized immunotherapy and addressing T cell availability issues within tumor sites, particularly when combined with existing therapies. This review discusses TMEs and the strategies to overcome immunosuppression in TME, and various immune cell-based strategies to improve antitumor response. It also focuses on the strategies for constructing microenvironment responsive nanoplatforms based upon the factors present at higher levels in TME like acidic pH, hypoxia facilitated by poor oxygen supply, higher expression of certain enzymes, and other factors such light, ultrasound and magnetic field. Combination immune therapies combined with immunotherapy include photodynamic therapy, photothermal therapy, chemotherapy, gene therapy and radiotherapy, revealing a high level of anticancer activity in comparison to a single therapy, enhancing immunogenicity, promoting therapeutic efficacy, and lowering metastasis. In conclusion, cancer immunotherapy is a potential technique to combat cancer cells and boost the immune system, hindering their growth and recurrence. In order to prevent cancer, it helps the immune system target cancer cells selectively and strengthens its long-term memory. Clinical trials are extending the application of immunotherapy and identifying strategies to improve the immune system tumor-fighting capabilities. Immunotherapy has enormous promise and gives hope for more successful cancer treatment.
免疫系统和癌细胞在肿瘤生长过程中相互作用错综复杂,免疫激活和抑制之间的动态相互作用极大地影响了癌症的结果。自然杀伤细胞 (NK)、细胞毒性 T 淋巴细胞 (CTL) 和树突状细胞 (DC) 采用多种机制来对抗癌症。然而,慢性炎症和免疫抑制性肿瘤微环境 (TME) 等因素带来的挑战,常常阻碍免疫细胞准确地检测和消除肿瘤的能力。免疫疗法提供了一种有前途的方法,通过重新编程免疫系统来靶向和消除癌细胞,同时最大限度地减少副作用,增强免疫记忆,并降低转移和复发的风险,与传统治疗方法(如放射治疗和手术)相比。纳米技术通过使纳米颗粒更安全、更有效地递送来提供了一种潜在的解决方案。这些纳米工程药物可以定制为受控激活和释放。改善 TME 特征有可能增强个性化免疫疗法,并解决肿瘤部位 T 细胞可用性问题,尤其是与现有疗法相结合时。这篇综述讨论了 TME 及其克服 TME 中免疫抑制的策略,以及各种基于免疫细胞的策略来改善抗肿瘤反应。它还重点介绍了基于 TME 中更高水平的因素(如酸性 pH 值、缺氧、某些酶的高表达以及光、超声和磁场等其他因素)构建微环境响应纳米平台的策略。与免疫疗法结合的联合免疫疗法包括光动力疗法、光热疗法、化学疗法、基因疗法和放射疗法,与单一疗法相比,显示出更高的抗癌活性,增强了免疫原性,提高了治疗效果,并降低了转移率。总之,癌症免疫疗法是一种对抗癌细胞和增强免疫系统的潜在技术,可以阻止其生长和复发。为了预防癌症,它有助于免疫系统有针对性地靶向癌细胞并增强其长期记忆。临床试验正在扩展免疫疗法的应用,并确定改善免疫系统抗癌能力的策略。免疫疗法具有巨大的潜力,为更成功的癌症治疗带来了希望。
Front Biosci (Landmark Ed). 2024-10-8
Acc Chem Res. 2019-5-23
Bioact Mater. 2020-12-26
Front Immunol. 2018-2-26
Discov Oncol. 2025-9-3
Int J Nanomedicine. 2025-6-13